Clinical Trial Update: Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of gemcitabine and celecoxib for pancreatic cancer after R0 resection; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Celecoxib (Celebrex) (celecoxib)
• Gemcitabine (Gemzar) (gemcitabine)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Pancreatic Cancer, Chemotherapy Effect | Phase 2 | Status: RECRUITING